Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 5th edn. Arlington, VA: American Psychiatric Publishing, 2013.

Dodick

Turkel

DeGryse

, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50(6): 921–936.

Metzler

Robertson

. Visual Snow Syndrome: Proposed Criteria, Clinical Implications, and Pathophysiology. Curr Neurol Neurosci Rep 2018; 18(8): 1–9.

Kim

D-Y

B-M

Paik

N-J

. Central Effect of Botulinum Toxin Type A in Humans. Int. J. Neurosci 2006; 116(6): 667–680.

A potential role for onabotulinumtoxinA in the management of Hallucinogen persisting perception disorder

Abstract

Get full access to this article

References